Top-Rated StocksTop-Rated CymaBay Therapeutics Stock Price, News & Analysis (NASDAQ:CBAY) $20.49 +0.07 (+0.34%) (As of 10:04 AM ET) Add Compare Share Share Today's Range$20.23▼$20.7650-Day Range$12.63▼$20.4252-Week Range$3.83▼$21.06Volume74,205 shsAverage Volume1.90 million shsMarket Capitalization$2.32 billionP/E RatioN/ADividend YieldN/APrice Target$22.27 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability CymaBay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.08 Rating ScoreUpside/Downside9.1% Upside$22.27 Price TargetShort InterestBearish10.50% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment-0.01Based on 2 Articles This WeekInsider TradingSelling Shares$3.09 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.94) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector804th out of 949 stocksPharmaceutical Preparations Industry365th out of 421 stocks 2.5 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.27, CymaBay Therapeutics has a forecasted upside of 9.1% from its current price of $20.42.Amount of Analyst CoverageCymaBay Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.50% of the outstanding shares of CymaBay Therapeutics have been sold short.Short Interest Ratio / Days to CoverCymaBay Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in CymaBay Therapeutics has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 1.1 News and Social Media Coverage News SentimentCymaBay Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CymaBay Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for CBAY on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,086,453.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($0.94) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -22.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -22.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 47.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CymaBay Therapeutics Stock (NASDAQ:CBAY)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.Read More CBAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBAY Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comShort Interest in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Increases By 9.1%December 2, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Hits New 1-Year High at $19.79December 6, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 26, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Trading 5.3% Higher November 24, 2023 | seekingalpha.comCBAY CymaBay Therapeutics, Inc.November 19, 2023 | seekingalpha.comCircling Back On CymaBay TherapeuticsNovember 18, 2023 | finance.yahoo.comInsider Sell Alert: President of R&D Charles Mcwherter Sells 11,342 Shares of CymaBay ...November 16, 2023 | finance.yahoo.comInsider Sell Alert: CEO Sujal Shah Divests 64,863 Shares of CymaBay Therapeutics IncDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | markets.businessinsider.comSuperior Efficacy, Safety, and Benefits of Seladelpar Boosts CymaBay Therapeutics’ Rating: Julian Harrison’s AnalysisNovember 15, 2023 | markets.businessinsider.comPromising Outlook for CymaBay Therapeutics: Superior Efficacy of Seladelpar in PBC Treatment Justifies Buy RatingNovember 15, 2023 | markets.businessinsider.comPromising Phase III Study Results Boost CymaBay’s Market Potential Amid Competitor Safety ConcernsNovember 14, 2023 | bizjournals.comEast Bay company's 'greatest biotech comeback' drives toward drug approval in rare liver diseaseNovember 13, 2023 | finance.yahoo.comCymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®November 10, 2023 | markets.businessinsider.comPromising Developments in CymaBay Therapeutics’ Seladelpar Program Drive ‘Buy’ RatingNovember 9, 2023 | morningstar.comCymaBay Therapeutics Inc CBAYNovember 9, 2023 | finance.yahoo.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | benzinga.comRecap: CymaBay Therapeutics Q3 EarningsNovember 8, 2023 | markets.businessinsider.comRaymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To KnowNovember 8, 2023 | finance.yahoo.comDoes CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?November 7, 2023 | finance.yahoo.comCymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)November 6, 2023 | markets.businessinsider.comWhere CymaBay Therapeutics Stands With AnalystsNovember 1, 2023 | finance.yahoo.comCymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary CholangitisOctober 31, 2023 | finance.yahoo.comCymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023October 26, 2023 | markets.businessinsider.comFDA’s Breakthrough Therapy Designation Expansion Bolsters CymaBay Therapeutics’ Buy RatingOctober 23, 2023 | finance.yahoo.comCymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023See More Headlines Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$22.27 High Stock Price Target$34.00 Low Stock Price Target$12.00 Potential Upside/Downside+9.1%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net MarginsN/A Pretax Margin-290.50% Return on Equity-62.69% Return on Assets-33.85% Debt Debt-to-Equity Ratio0.32 Current Ratio22.76 Quick Ratio22.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book47.49Miscellaneous Outstanding Shares113,400,000Free Float105,465,000Market Cap$2.32 billion OptionableOptionable Beta0.34 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Sujal A. Shah (Age 50)President, CEO & Director Comp: $1.04MDr. Charles A. McWherter Ph.D. (Age 68)President of Research & Development and Chief Scientific Officer Comp: $700.65kMr. Paul T. Quinlan (Age 60)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $629.72kMr. Harish Shantharam C.F.A.Chief Financial OfficerMr. Ken BoehmSenior Vice President of Human ResourcesMr. Patrick J. O'Mara (Age 62)Senior Vice President of Business Development Dr. Robert L. Martin (Age 61)Senior Vice President of Manufacturing & Nonclinical Development Ms. Klara A. Dickinson-Eason (Age 55)Chief Regulatory & Quality Assurance Officer Comp: $441.84kMs. Becki Filice (Age 62)Senior Vice President of Portfolio & Product Leadership Mr. Lewis J. Stuart B.A. (Age 64)M.B.A., Chief Commercial Officer Comp: $378.79kMore ExecutivesKey CompetitorsIndiviorNASDAQ:INDVRocket PharmaceuticalsNASDAQ:RCKTSchrödingerNASDAQ:SDGRCrinetics PharmaceuticalsNASDAQ:CRNXGemini TherapeuticsNASDAQ:GMTXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 369,851 shares on 11/24/2023Ownership: 0.402%Walleye Capital LLCSold 186,847 shares on 11/21/2023Ownership: 0.042%Charles McwherterSold 11,342 sharesTotal: $207,331.76 ($18.28/share)GTS Securities LLCBought 36,600 shares on 11/16/2023Ownership: 0.000%Tudor Investment Corp Et AlBought 24,769 shares on 11/16/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions CBAY Stock Analysis - Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CBAY shares. View CBAY analyst ratings or view top-rated stocks. What is CymaBay Therapeutics' stock price target for 2024? 12 analysts have issued 12-month target prices for CymaBay Therapeutics' stock. Their CBAY share price targets range from $12.00 to $34.00. On average, they expect the company's stock price to reach $22.27 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. How have CBAY shares performed in 2023? CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 225.7% and is now trading at $20.42. View the best growth stocks for 2023 here. Are investors shorting CymaBay Therapeutics? CymaBay Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 11,910,000 shares, an increase of 9.1% from the October 31st total of 10,920,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 5.3 days. View CymaBay Therapeutics' Short Interest. When is CymaBay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our CBAY earnings forecast. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. During the same period in the previous year, the business posted ($0.28) earnings per share. What ETFs hold CymaBay Therapeutics' stock? ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.12%), Adage Capital Partners GP L.L.C. (3.64%), Jennison Associates LLC (3.22%), Fred Alger Management LLC (1.92%), FMR LLC (1.38%) and Affinity Asset Advisors LLC (1.00%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Kurt Von Emster, Paul T Quinlan and Sujal Shah. View institutional ownership trends. How do I buy shares of CymaBay Therapeutics? Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CBAY) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.